ACE Report Cover
First-Dose Tolerability of Tramadol-Celecoxib Co-Crystal vs Tramadol in Acute Pain
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
FOOT & ANKLE
First-Dose Tolerability of Tramadol-Celecoxib Co-Crystal vs Tramadol in Acute Pain

Adverse Reactions Following First-Dose Administration of Co-Crystal of Tramadol-Celecoxib Versus Tramadol Alone for Moderate-To-Severe Acute Pain.

Pain Ther . 2025 Jun;14(3):1147-1154.

Three hundred sixty-seven patients with moderate-to-severe acute postoperative pain following first metatarsal osteotomy were analyzed after receiving a first dose of CTC 200 mg (n=183) or tramadol 50 mg (n=183). The pupose was to provide a descriptive snapshot of first-dose tolerability. The primary outcome of interest for this post-hoc analysis was the prevalence of study drug–related, opioid-associated adverse reactions (somnolence, nausea, dizziness, vomiting) at 2, 4, and 6 hours after the first dose; no formal inferential testing was planned. Outcomes were assessed up to 6 hours (just prior to the second dose). Overall, the results revealed similar proportions of these adverse reactions at each timepoint between CTC and tramadol despite the higher tramadol content in CTC (88 mg vs 50 mg). These findings suggest first-dose tolerability of CTC is comparable to tramadol 50 mg in this setting.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. First-Dose Tolerability of Tramadol-Celecoxib Co-Crystal vs Tramadol in Acute Pain. ACE Report. 2025;307(9):9. Available from: https://myorthoevidence.com/AceReport/Show/first-dose-tolerability-of-tramadol-celecoxib-co-crystal-vs-tramadol-in-acute-pain

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report